
    
      Understanding characteristics of patients who switched from a 4/2 to a 2/1 sunitinib schedule
      or initiated the 2/1 schedule in Brazil, and the resulting clinical outcomes in the
      real-world setting

      â€¢ Describing the occurrence of AEs on the 4/2 and 2/1 schedules
    
  